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chemotherapy, and five were severely neutropenic. All had fever
and severe pain over the area involved (4 with calves involve-
ment, 1 with thigh and 1 with axilla). Three were hypotensive
and two required ICU care. Two patients were complicated with
abscess development and two expired, despite adequate therapy
with meropenem and amikacin. MRI findings were compatible with
myositis. All E. coli isolates were resistant to quinolones. Moreover
33% were ESBL positive. Only five isolates were recovered and all
belonged to the B2 phylogenetic group. PCR analysis of these E. coli
showed similar virulence profile, with presence of uidA, adhesins
iha and fimH, toxin sat, siderophores fyuA and iutA, invasins KpsII,
usp, traT, ompT and PAI.
Conclusions: E. coli pyomyositis is an extremely rare clinical man-
ifestation that has emerged as a new problem in our hemato-
logic malignancy patients, and is associated with a high mortal-
ity (33.3%). Our molecular analysis showed that the isolates have
the same phylogenetic background. Moreover, all have similar vir-
ulence factors profile which indicates that these E. coli may have
acquired special properties to be able to invade the muscle. Our
findings provide novel insights into the molecular epidemiology of
invasive extraintestinal E. coli infections. Current studies are on-
going to further characterize this disease and to target the vir-
ulence factors for the potential development of preventive mea-
sures, such as vaccines.
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Using Serum Galactomannan Levels to Guide Early
Anti-fungal Therapy in Haematology Patients at Risk of
Invasive Aspergillosis
Ban Hock Tan, Nidhi Chlebicka, Jenny Guek Hong Low, Gee
Chuan Wong. Infectious Diseases Unit, Department of Internal
Medicine, Singapore General Hospital, Singapore
Background: Patients with prolonged neutropenia are at risk of in-
vasive aspergillosis. Empirical broad-spectrum anti-fungals after 4
7 days of antibiotics have been the standard of care, but might
mean needless treatment in some patients.
Objectives: To determine if serial Galactomannan (GM) monitor-
ing, in the setting of effective anti-candidal prophylaxis, permits
targeted, pre-emptive therapy in those at greatest risk, and spare
febrile patients without evidence of fungal infection other than
prolonged fever from unnecessary and potentially toxic therapy.
Methods: This is a prospective, randomized, non-blinded study
comparing two different strategies. Standard definitions of proven
and probable invasive mold infections were used. Eligible patients
were those with acute leukemias or myelodysplastic syndrome on
induction, re-induction, consolidation or salvage chemotherapy;
patients undergoing bone marrow transplantation; and patients
with severe aplastic anemia on Antithymocyte Globulin. Patients
in the study arm underwent serial GM monitoring and were given
early pre-emptive anti-fungal therapy using an appropriate anti-
fungal agent only if 2 consecutive GM antigen tests were positive
or if they had one positive GM test and a highly suggestive CT tho-
rax. The patients in the control arm were given the standard of
care in accordance with the published guidelines for patients with
febrile neutropenia i.e. no regular GM monitoring, but empirical
antifungals if there was unexplained neutropenic fever after 4-7
days of broad-spectrum antibiotics.
Results: A total of 58 patients were recruited. One hundred and
eighty-six GM tests were performed. The mean number of GM tests
was 2.7 per patient. Duration of neutropenia was 14.4 days in mon-
itoring arm versus 11.4 days in control arm (p=0.133). One patient
in the study arm developed proven IA and one developed prob-
able IA. There was no IA in the control arm. Excluding patients
with probable/proven IA, 7 patients in the monitoring arm and
13 patients in the control arm were started on amphotericin or
voriconazole or caspofungin. There was no difference in the num-
ber of deaths (62.5% vs 37.5%, p= 0.709).
Conclusion: Serial GM monitoring is a simple, non-invasive adjunct
in the management of patients at high risk of IA in the setting of
prolonged febrile neutropenia. Concerns about molds other than
aspergillus limit its usefulness.
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Rothia mucilaginosus, an Uncommon Cause of Bacteremia
in Immunocompromised Patients: Case Report and
Literature Review
Vicki Morrison, Shulasmith Bonham. Veterans Affairs Medical
Center, Minneapolis, MN, USA
Background/Objectives/Methods: We report a case of fatal bac-
teremia caused by Rothia mucilaginosus in a neutropenic patient.
The literature on infections with this pathogen is reviewed.
Results: This 67 yr old male had CLL/SLL, for which he had re-
ceived fludarabine-based therapy. He developed a Richter' s trans-
formation, treated with combination chemotherapy. More recently
he had been diagnosed with hemophagocytic lymphohistiocytosis,
related to possible EBV infection, treated with ganciclovir, IVIG,
dexamethasone, and cyclosporine. He was admitted for febrile
neutropenia, and placed on broad spectrum antimicrobial ther-
apy. Vancomycin was added after coagulase negative staph bac-
teremia was diagnosed. After initial improvement, he developed
fever, diarrhea, myalgias, and fatigue. WBC was <100 cells/mm3,
hgb 10.0 g/dl, and platelet count 20,000. EBV PCR, CMV PCR, and
viral cultures were negative. He was begun on empiric vancomycin,
ceftazidime, and metronidazole. Initial blood cultures revealed
Gram-positive cocci (GPC). He developed hypotension and hypoxia
with continued fevers, with repeat blood cultures (PICC, port, pe-
ripheral blood) growing GPC. Linezolid was added, with concerns
for VRE. The patient deteriorated and died. Stomatococcus mu-
cilaginosus was grown from the initial blood cultures. Rothia mu-
cilaginosus (Micrococcus mucilaginosus, Staphylococcus salivarius,
Stomatococcus mucilaginous) is part of the normal flora of the oral
cavity/upper respiratory tract. This GPC is weakly catalase posi-
tive or negative. Colonies are clear to whitish, mucoid, and adher-
ent to media. This organism has been implicated in cases of bac-
teremia (neutropenic patients), meningitis (pediatric patients with
malignancy, SCT), endocarditis (IV drug user), pneumonia, lung ab-
scess, and peritonitis. Risk factors for infection include immuno-
compromise, neutropenia, mucositis, and broad spectrum antimi-
crobial therapy. By in vitro susceptibility testing, penicillins and
cephalosporins are the treatment of choice.
Conclusion: Rothia mucilaginosus is a relatively uncommon Gram-
positive organism that must also be considered in the differential
diagnosis of bacteremia, meningitis, and respiratory tract infec-
tions in immunocompromised hosts.
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Epidemiology and Mortality of the Multidrug Resistant
Gram-negative Bloodstream Infection in Acute Myeloid
Leukemia
Janaina Midori Goto1, Maria Daniela Di Dea Bergamasco1, James
Farley Maciel2, Maria de Lourdes Chauffaille2, Paola Cappellano1,
Carlos Alberto Pires Pereira1. 1Universidade Federal de São Paulo,
Escola Paulista de Medicina, Infectology Department, Sao Paulo,
Brazil; 2Universidade Federal de São Paulo, Escola Paulista de
Medicina, Hematology Department, Sao Paulo, Brazil
Background: In the last few decades the epidemiology of infections
in neutropenic patient had changed, reflecting prophylaxis and an-
